Stephanie Riolo, MD
Child & Adolescent Psychiatry · Dayton, OHNPI 1942237425
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Supernus Pharmaceuticals, Inc. accounts for 82.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $6,648 and has fallen 92.3% since, to $510 in 2025. Among child & adolescent psychiatry clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $128.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$7K
- Neurocrine Biosciences, Inc.$262
- Johnson & Johnson$222
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$194
- E.r. Squibb & Sons, L.L.C.$191
- Sunovion Pharmaceuticals Inc.$178
- plus $441 from 8 others
What the payments were for
- Speaking & faculty fees$4,62555%
- Travel & lodging$1,63120%
- Food & beverage$1,96624%
- Education$1161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$6,465
- COBENFY$121
- INVEGA SUSTENNA$121
- INGREZZA$119
- LATUDA$117
- CAPLYTA$112
- Jornay PM 20mg capsules (Bottle of 100)$111
How this compares
$8,338 in reported general payments places this provider in the 90th percentile of 160 child & adolescent psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $42,975 |
| Abilify MaintenaAripiprazole | 13 | $35,971 |
| CaplytaLumateperone Tosylate | 19 | $30,796 |
| Lamotrigine ErLamotrigine | 70 | $13,302 |
| TrintellixVortioxetine Hydrobromide | 23 | $12,845 |
| Cotempla Xr-OdtMethylphenidate | 19 | $9,756 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,545 |
| Paliperidone ErPaliperidone | 16 | $3,862 |
| Quetiapine Fumarate | 126 | $3,243 |
| Lurasidone Hcl | 36 | $3,056 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 46 | $2,947 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 45 | $2,763 |
| Clozapine | 21 | $1,588 |
| Buspirone Hcl | 82 | $1,576 |
| Divalproex Sodium | 72 | $1,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $222 | $42,97512 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $90 | $35,97113 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $194 | $30,79619 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $28 | $17,39035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 160 child & adolescent psychiatry providers in Ohio.
Other child & adolescent psychiatry in Dayton
- Nimisha ThuluvathDayton$313
- Theresa Blachly-FlanaganDayton$297
- Rick BowersMoraine$182K
- Robert FindlingCleveland$125K
- Joseph RiemanFremont$56K
- Melissa DelbelloCincinnati$36K
- Andre ProchoroffCleveland$26K
- Peter GoldenAkron$21K
- Daniel WeisMiddletown$13K
- John VraciuCanton$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.